RMD – UBS rates the stock as Buy

ResMed will report its second-quarter results on January 29, 2021. UBS expects revenue growth to be 5.2% for the US, Canada and Latin America. Gross margin is expected to consistent with the first quarter at 59.9%.

Total global ventilator sales are forecast to be US$43m versus US$31m in the last year and US$70m in the first quarter. UBS believes ResMed will continue to penetrate the large addressable patient population encompassing a spectrum of respiratory diseases.

The Buy rating is unchanged with a target of $US241.

Sector: Health Care Equipment & Services.


Current Price is $27.90. Target price not assessed.



Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →